Diarrhea-predominant Irritable Bowel Syndrome (IBS-D), the most common form of IBS in the U.S., is a chronic and debilitating illness characterized by recurrent abdominal pain or discomfort associated with altered bowel function.The etiology of IBS is not understood and its underlying cause remains unknown. It can significantly impact patient quality of life physically, emotionally, socially and economically.
RHB-102 is a proprietary, oral, bi-modal extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron.
RedHill has completed a positive U.S. Phase 2 study with RHB-102 12 mg in IBS-D, meeting the primary endpoint of improvement of stool consistency response (per FDA guidance definition).
Read more about the study results here.